Literature DB >> 10711239

From Halsted to prevention and beyond: advances in the management of breast cancer during the twentieth century.

B Fisher1.   

Abstract

This commentary evaluates progress made in the treatment of breast cancer during the twentieth century. Most of the period from 1900 to 1970 was governed by the 'non-science' of anecdotalism and classical inductivism and was marked by the absence of a scientific gestalt. In keeping with the Halstedian concept that breast cancer was a local disease that spread throughout the body by contiguous extension and could be cured by more expansive surgery, the disease was treated with radical surgery. In 1950, however, a new era of enlightenment began to emerge. The awareness that there was a scientific process in which hypotheses generated from laboratory and clinical investigation could be tested by means of randomised clinical trials was a seminal advance, as were findings from studies that laid the groundwork for the modern era of steroid hormone action, including identification of oestrogen receptors. Expanding knowledge regarding tumour cell kinetics, tumour heterogeneity, and technological advances related to mammography and radiation therapy were also to play a role in making possible the advances in therapy that were subsequently to occur. In the past 30 years, as a result of laboratory and clinical investigation, the Halstedian thesis of cancer surgery was displaced by an alternative hypothesis that was supported by findings from subsequent clinical trials. A new paradigm governed surgery for breast cancer, and lumpectomy followed by radiation therapy became accepted practice. A second paradigm that governed the use of adjuvant systemic therapy arose as a result of laboratory and clinical investigation. Treating patients who were free of identifiable metastatic disease with systemic adjuvant therapy because some of them might develop distant disease in the future was a revolutionary departure from prior treatment strategy and became a new exemplar. Not only did the chemotherapy favourably alter the outcome of breast cancer patients, but the anti-oestrogen tamoxifen benefited patients with all stages of the disease. Tamoxifen also reduced the incidence of contralateral breast cancer, as well as tumour in the ipsilateral breast following lumpectomy. The use of preoperative therapy was also found to enhance breast-conserving surgery in women with large tumours, although its value in other circumstances is still being defined. The observation that, as a result of tamoxifen administration, invasive and non-invasive breast cancers can be prevented in women who are at increased risk for such tumours, and the finding that pathological entities such as atypical hyperplasia, lobular carcinoma in situ (LCIS) and intraductal carcinoma (DCIS) can identify women who should be considered candidates for tamoxifen serve as a fitting capstone to the accomplishments of the twentieth century. Breast cancer prevention has now become a reality. Unfortunately, a variety of circumstances have arisen as the result of advances in the understanding and treatment of breast cancer over the last 30 years that threaten to nullify the progress that has been achieved. This distressing phenomenon may be reviewed as a 'paradox of accomplishment'. The numerous uncertainties, issues and questions that have arisen following the report of each advance in treatment, the surfeit of new information that has not yet been integrated into treatment strategies, the undesirable consequences of enhanced tumour detection, a reversion to Halstedianism and anecdotalism, and the uncertainty of therapeutic decision making resulting from the demonstration of small but statistically significant benefits, particularly in patients with good prognosis, need to be addressed. Inappropriate interpretation of those circumstances threatens to deny women with breast cancer and those at high risk for the disease the opportunity to benefit from treatments that have been proven to be of worth. Perhaps the most important accomplishment of the twentieth century relates to the change in the pro

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10711239     DOI: 10.1016/s0959-8049(99)00217-8

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  28 in total

1.  Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1.

Authors:  Yeong-Gwan Park; Xiaohong Zhao; Fabienne Lesueur; Douglas R Lowy; Mindy Lancaster; Paul Pharoah; Xiaolan Qian; Kent W Hunter
Journal:  Nat Genet       Date:  2005-09-04       Impact factor: 38.330

2.  Adjuvant Therapy Choices in Patients With Resected Non-Small-Cell Lung Cancer: Correlation of Doctors' Treatment Plans and Relevant Phase III Trial Data.

Authors:  Mark R Green; Michele Andrews; Richard Leff; Joanne Willey; Carmen Allegra; Alex Denes; James Epstein; James Jones; Lee Lokey
Journal:  J Oncol Pract       Date:  2005-07       Impact factor: 3.840

Review 3.  The role of radiation therapy in the treatment of metastatic cancer.

Authors:  Baldassarre Stea; Tijana Skrepnik; Charles C Hsu; Roy Abendroth
Journal:  Clin Exp Metastasis       Date:  2018-07-30       Impact factor: 5.150

4.  Experiencing Cancer. An Ethnographic Study on Illness and Disease.

Authors:  Christine Holmberg
Journal:  Recent Results Cancer Res       Date:  2021

5.  Modeling the effect of tumor size in early breast cancer.

Authors:  Claire Verschraegen; Vincent Vinh-Hung; Gábor Cserni; Richard Gordon; Melanie E Royce; Georges Vlastos; Patricia Tai; Guy Storme
Journal:  Ann Surg       Date:  2005-02       Impact factor: 12.969

6.  Preservation of the nipple-areola complex in skin-sparing mastectomy for early breast cancer.

Authors:  Ryo Miyake; Satoki Kinoshita; Naoko Shimada; Ken Uchida; Hiroshi Takeyama; Toshiaki Morikawa
Journal:  Surg Today       Date:  2018-02-21       Impact factor: 2.549

7.  How to perform a NAC sparing mastectomy using an ADM and an implant.

Authors:  Gudjon Leifur Gunnarsson; Mikkel Børsen-Koch; Peter Wamberg; Jørn Bo Thomsen
Journal:  Gland Surg       Date:  2014-11

8.  A "universal" model of metastatic cancer, its parametric forms and their identification: what can be learned from site-specific volumes of metastases.

Authors:  Leonid Hanin; Karen Seidel; Dietrich Stoevesandt
Journal:  J Math Biol       Date:  2015-08-26       Impact factor: 2.259

Review 9.  History of lymphadenectomy for esophageal cancer and the future prospects for esophageal cancer surgery.

Authors:  Hiromasa Fujita
Journal:  Surg Today       Date:  2014-02-13       Impact factor: 2.549

10.  Surgical outcome of patients with core-biopsy-proven nonpalpable breast carcinoma: a large cohort follow-up study.

Authors:  S van Esser; N H G M Peters; M A A J van den Bosch; W P Th M Mali; P H M Peeters; I H M Borel Rinkes; R van Hillegersberg
Journal:  Ann Surg Oncol       Date:  2009-05-13       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.